(Q40362742)

18 July 2018

title

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death (English)

1 reference

18 July 2018

1 reference

5

David Dingli

1 reference

18 July 2018

24

Angela Dispenzieri

1 reference

18 July 2018

22

Robert A Kyle

1 reference

18 July 2018

4

Martha Q Lacy

1 reference

18 July 2018

17

Stephen Russell

1 reference

18 July 2018

S. Vincent Rajkumar

23

S Vincent Rajkumar

1 reference

18 July 2018

Morie A Gertz

2

Morie A Gertz

1 reference

18 July 2018

Suzanne R Hayman

8

Suzanne R Hayman

1 reference

18 July 2018

Steven R Zeldenrust

21

Steven Zeldenrust

1 reference

18 July 2018

John A. Lust

18

John A Lust

1 reference

18 July 2018

Taxiarchis Kourelis

16

Taxiarchis V Kourelis

1 reference

18 July 2018

Francis K Buadi

6

Francis K Buadi

1 reference

18 July 2018

Shaji K Kumar

3

Shaji K Kumar

1 reference

18 July 2018

Wilson I Gonsalves

14

Wilson Gonsalves

1 reference

18 July 2018

Ronald S Go

20

Ronald S Go

1 reference

18 July 2018

Miriam A Hobbs

12

Miriam Hobbs

1 reference

18 July 2018

Prashant Kapoor

9

Prashant Kapoor

1 reference

18 July 2018

Yi Lisa Hwa

13

Yi Lisa Hwa

1 reference

18 July 2018

P A Amie Fonder

11

Amie Fonder

1 reference

18 July 2018

Rahma Warsame

15

Rahma Warsame

1 reference

18 July 2018

Eli Muchtar

1

Eli Muchtar

1 reference

18 July 2018

Martha Grogan

7

Martha Grogan

1 reference

18 July 2018

author name string

Nelson Leung

10

1 reference

18 July 2018

Yi Lin

19

1 reference

18 July 2018

language of work or name

English

0 references

publication date

26 January 2017

1 reference

18 July 2018

published in

Blood

1 reference

18 July 2018

volume

129

1 reference

18 July 2018

issue

15

1 reference

18 July 2018

page(s)

2111-2119

1 reference

18 July 2018

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Amyloidosis: diagnosis and management

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391625

High-dose therapy and autologous transplantation in amyloidosis-AL

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28126928

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2016-11-751628

1 reference

18 July 2018

PMCID

5391625

1 reference

18 July 2018

PubMed ID

28126928

1 reference

18 July 2018